Reassessment of Radiation Exposure From Bone Scintigraphy

IF 2.1 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current drug metabolism Pub Date : 2023-12-23 DOI:10.2174/0113892002274982231211102127

Handan Tanyildizi-Kökkülünk, Ahmet Murat Şenişik, Mahmut Yüksel

{"title":"Reassessment of Radiation Exposure From Bone Scintigraphy","authors":"Handan Tanyildizi-Kökkülünk, Ahmet Murat Şenişik, Mahmut Yüksel","doi":"10.2174/0113892002274982231211102127","DOIUrl":null,"url":null,"abstract":"Aim: This study was aimed to re-determine the radiation dose rate emitted from the patients who underwent bone scintigraphy Material and Methods: A mean of 20.87±2.54 mCi 99mTc-MDP was injected into patients. A GM counter was used to measure dose rates in 3 different periods, at intervals of 25, 50, 100, 150, and 200 cm from the patient's anterior for head, thorax, abdomen, and pelvis levels. Measurements were used to determine patient-induced environmental doses and radiation doses to personnel/patient relatives. Results and Discussion: There were strong correlations between mean dose rate (mRh-1mCi-1) and time at all regions and distances. The received dose for staff was calculated between a range of 0.01-0.02 mSv/mCi per patient. The total dose to be received by the companion was estimated to be between 0.019-0.039 and 0.011-0.022 mSv for public and personal vehicle transportation, respectively. The radiation dose exposed by nurses (4th, 6th, and 8th hours after injection) was found to be 0.012-0.064, 0.006-0.038, and 0.002-0.018 mSv/patient, respectively. Conclusion: The fact that the doses of personnel and patient relatives in the study were below the legal limits shows that the study was carried out within a safe range. However, in terms of radiation protection, it is necessary to limit the time spent with the patient as much as possible and increase the distance. Since the dangers of low radiation dosages are unknown, there is a need to inform the patient's relatives and staff about the potential risks.","PeriodicalId":10770,"journal":{"name":"Current drug metabolism","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892002274982231211102127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study was aimed to re-determine the radiation dose rate emitted from the patients who underwent bone scintigraphy Material and Methods: A mean of 20.87±2.54 mCi 99mTc-MDP was injected into patients. A GM counter was used to measure dose rates in 3 different periods, at intervals of 25, 50, 100, 150, and 200 cm from the patient's anterior for head, thorax, abdomen, and pelvis levels. Measurements were used to determine patient-induced environmental doses and radiation doses to personnel/patient relatives. Results and Discussion: There were strong correlations between mean dose rate (mRh-1mCi-1) and time at all regions and distances. The received dose for staff was calculated between a range of 0.01-0.02 mSv/mCi per patient. The total dose to be received by the companion was estimated to be between 0.019-0.039 and 0.011-0.022 mSv for public and personal vehicle transportation, respectively. The radiation dose exposed by nurses (4th, 6th, and 8th hours after injection) was found to be 0.012-0.064, 0.006-0.038, and 0.002-0.018 mSv/patient, respectively. Conclusion: The fact that the doses of personnel and patient relatives in the study were below the legal limits shows that the study was carried out within a safe range. However, in terms of radiation protection, it is necessary to limit the time spent with the patient as much as possible and increase the distance. Since the dangers of low radiation dosages are unknown, there is a need to inform the patient's relatives and staff about the potential risks.

查看原文本刊更多论文

重新评估骨闪烁成像的辐射量

目的：本研究旨在重新确定接受骨闪烁扫描的患者的辐射剂量率：向患者平均注射 20.87±2.54 mCi 99m锝-MDP。使用 GM 计数器测量 3 个不同时间段的剂量率，距离患者前方 25、50、100、150 和 200 厘米处分别为头部、胸部、腹部和骨盆水平。测量结果用于确定患者引起的环境剂量和人员/患者亲属受到的辐射剂量。结果与讨论：所有区域和距离的平均剂量率（mRh-1mCi-1）与时间之间都有很强的相关性。工作人员的接收剂量计算范围为 0.01-0.02 mSv/mCi/每名患者。据估计，陪同人员在公共交通工具和私人交通工具上受到的总剂量分别为 0.019-0.039 毫希沃特和 0.011-0.022 毫希沃特。护士（注射后第 4、第 6 和第 8 小时）/患者受到的辐射剂量分别为 0.012-0.064、0.006-0.038 和 0.002-0.018 mSv。结论研究人员和患者亲属的剂量均低于法定限值，这表明研究是在安全范围内进行的。然而，在辐射防护方面，有必要尽可能限制与患者在一起的时间并增加距离。由于低剂量辐射的危害尚不清楚，因此有必要向病人亲属和工作人员告知潜在的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug metabolism 医学-生化与分子生物学

CiteScore

4.30

自引率

4.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism. More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.